ENTRY       hsa05207                    Pathway
NAME        Chemical carcinogenesis - receptor activation - Homo sapiens (human)
DESCRIPTION Carcinogenesis is a multistage process that consists of initiation, promotion, and progression stages. Chemicals or environmental factors may act at any of these stages to induce and/or enhance the carcinogenic process. Based on their mode-of-action, carcinogens can be classified as genotoxic or non-genotoxic. Genotoxic agent begins their action at the deoxyribonucleic acid (DNA) level, causing DNA damage through several mechanisms. Non-genotoxic carcinogens are chemicals that cause the development of tumors through multiple non-genotoxic events and epigenetic alterations without direct interaction with DNA. One non-genotoxic mechanism involves receptor activation. Biological mechanisms involving receptor activation fall into two broad categories: (i) those that involve cell surface receptors and some intracellular receptors that activate signal transduction pathways, resulting in biological responses, including gene transcription, and (ii) those that involve intracellular receptors that translocate into the nucleus and act as transcription factors regulating gene expression. Both classes of receptors can be involved in mechanisms of carcinogenesis.
CLASS       Human Diseases; Cancer: overview
PATHWAY_MAP hsa05207  Chemical carcinogenesis - receptor activation
NETWORK     nt06210  ERK signaling (cancer)
            nt06214  PI3K signaling (cancer)
            nt06219  JAK-STAT signaling (cancer)
            nt06227  Nuclear receptor signaling (cancer)
            nt06230  Cell cycle (cancer)
            nt06234  cAMP signaling (cancer)
  ELEMENT   N01337  NNK/NNN to CHRNA7-E2F signaling pathway
            N01339  NNK/NNN to PI3K signaling pathway
            N01341  NNK/NNN to Jak-STAT signaling pathway
            N01342  Nicotine to Jak-STAT signaling pathway
            N01344  NNK/NNN to RAS-ERK signaling pathway
            N01346  Nicotine/NNK to cAMP signaling pathway
            N01348  Nicotine/NNK to PI3K signaling pathway
            N01350  NNK/NNN to PI3K signaling pathway
            N01352  BPA to RAS-ERK signaling pathway
            N01353  E2 to RAS-ERK signaling pathway
            N01354  BPA to RAS-ERK signaling pathway
            N01355  Arsenic to PI3K signaling pathway
            N01357  P4/MPA to membrane-initiated progesterone signaling pathway
            N01359  P4/MPA to PR-PI3K signaling pathway
            N01361  P4/MPA to PR-RAS-ERK signaling pathway
            N01363  P4/MPA to nuclear-initiated progesterone signaling pathway
            N01364  E2 to nuclear-initiated estrogen signaling pathway
            N01365  TCDD to Ahr signaling pathway
            N01366  BaP to Ahr signaling pathway
            N01367  PCB to Ahr signaling pathway
            N01368  HCB to Ahr signaling pathway
DRUG        D11045  Darolutamide (JAN/USAN/INN)
ORGANISM    Homo sapiens (human) [GN:hsa]
GENE        10000  AKT3; AKT serine/threonine kinase 3 [KO:K04456] [EC:2.7.11.1]
            10488  CREB3; cAMP responsive element binding protein 3 [KO:K09048]
            10683  DLL3; delta like canonical Notch ligand 3 [KO:K06051]
            107  ADCY1; adenylate cyclase 1 [KO:K08041] [EC:4.6.1.1]
            10720  UGT2B11; UDP glucuronosyltransferase family 2 member B11 [KO:K00699] [EC:2.4.1.17]
            10728  PTGES3; prostaglandin E synthase 3 [KO:K15730] [EC:5.3.99.3]
            108  ADCY2; adenylate cyclase 2 [KO:K08042] [EC:4.6.1.1]
            109  ADCY3; adenylate cyclase 3 [KO:K08043] [EC:4.6.1.1]
            10941  UGT2A1; UDP glucuronosyltransferase family 2 member A1 complex locus [KO:K00699] [EC:2.4.1.17]
            110117499  P3R3URF-PIK3R3; P3R3URF-PIK3R3 readthrough [KO:K02649]
            111  ADCY5; adenylate cyclase 5 [KO:K08045] [EC:4.6.1.1]
            112  ADCY6; adenylate cyclase 6 [KO:K08046] [EC:4.6.1.1]
            113  ADCY7; adenylate cyclase 7 [KO:K08047] [EC:4.6.1.1]
            1136  CHRNA3; cholinergic receptor nicotinic alpha 3 subunit [KO:K04805]
            1137  CHRNA4; cholinergic receptor nicotinic alpha 4 subunit [KO:K04806]
            1139  CHRNA7; cholinergic receptor nicotinic alpha 7 subunit [KO:K04809]
            114  ADCY8; adenylate cyclase 8 [KO:K08048] [EC:4.6.1.1]
            1141  CHRNB2; cholinergic receptor nicotinic beta 2 subunit [KO:K04813]
            1143  CHRNB4; cholinergic receptor nicotinic beta 4 subunit [KO:K04815]
            115  ADCY9; adenylate cyclase 9 [KO:K08049] [EC:4.6.1.1]
            119391  GSTO2; glutathione S-transferase omega 2 [KO:K00799] [EC:2.5.1.18]
            1385  CREB1; cAMP responsive element binding protein 1 [KO:K05870]
            1386  ATF2; activating transcription factor 2 [KO:K04450]
            1388  ATF6B; activating transcription factor 6 beta [KO:K09049]
            148327  CREB3L4; cAMP responsive element binding protein 3 like 4 [KO:K09048]
            153  ADRB1; adrenoceptor beta 1 [KO:K04141]
            154  ADRB2; adrenoceptor beta 2 [KO:K04142]
            1543  CYP1A1; cytochrome P450 family 1 subfamily A member 1 [KO:K07408] [EC:1.14.14.1]
            1544  CYP1A2; cytochrome P450 family 1 subfamily A member 2 [KO:K07409] [EC:1.14.14.1]
            1545  CYP1B1; cytochrome P450 family 1 subfamily B member 1 [KO:K07410] [EC:1.14.14.1]
            155  ADRB3; adrenoceptor beta 3 [KO:K04143]
            1555  CYP2B6; cytochrome P450 family 2 subfamily B member 6 [KO:K17709] [EC:1.14.14.-]
            1576  CYP3A4; cytochrome P450 family 3 subfamily A member 4 [KO:K17689] [EC:1.14.13.32 1.14.14.55 1.14.14.56 1.14.14.57 1.14.14.73 1.14.14.-]
            164091  PAQR7; progestin and adipoQ receptor family member 7 [KO:K25039]
            182  JAG1; jagged canonical Notch ligand 1 [KO:K06052]
            1869  E2F1; E2F transcription factor 1 [KO:K17454]
            1950  EGF; epidermal growth factor [KO:K04357]
            1956  EGFR; epidermal growth factor receptor [KO:K04361] [EC:2.7.10.1]
            196  AHR; aryl hydrocarbon receptor [KO:K09093]
            196883  ADCY4; adenylate cyclase 4 [KO:K08044] [EC:4.6.1.1]
            1978  EIF4EBP1; eukaryotic translation initiation factor 4E binding protein 1 [KO:K07205]
            2052  EPHX1; epoxide hydrolase 1 [KO:K01253] [EC:3.3.2.9]
            2053  EPHX2; epoxide hydrolase 2 [KO:K08726] [EC:3.3.2.10 3.1.3.76]
            207  AKT1; AKT serine/threonine kinase 1 [KO:K04456] [EC:2.7.11.1]
            208  AKT2; AKT serine/threonine kinase 2 [KO:K04456] [EC:2.7.11.1]
            2099  ESR1; estrogen receptor 1 [KO:K08550]
            2100  ESR2; estrogen receptor 2 [KO:K08551]
            221357  GSTA5; glutathione S-transferase alpha 5 [KO:K00799] [EC:2.5.1.18]
            2247  FGF2; fibroblast growth factor 2 [KO:K18497]
            2248  FGF3; fibroblast growth factor 3 [KO:K04358]
            2249  FGF4; fibroblast growth factor 4 [KO:K04358]
            2250  FGF5; fibroblast growth factor 5 [KO:K04358]
            2251  FGF6; fibroblast growth factor 6 [KO:K04358]
            2252  FGF7; fibroblast growth factor 7 [KO:K04358]
            2253  FGF8; fibroblast growth factor 8 [KO:K04358]
            2254  FGF9; fibroblast growth factor 9 [KO:K04358]
            2255  FGF10; fibroblast growth factor 10 [KO:K04358]
            2353  FOS; Fos proto-oncogene, AP-1 transcription factor subunit [KO:K04379]
            23633  KPNA6; karyopherin subunit alpha 6 [KO:K15042]
            23746  AIPL1; AIP like 1 HSP90 co-chaperone [KO:K17767]
            2475  MTOR; mechanistic target of rapamycin kinase [KO:K07203] [EC:2.7.11.1]
            253152  EPHX4; epoxide hydrolase 4 [KO:K22369] [EC:3.3.-.-]
            25774  GSTT4; glutathione S-transferase theta 4 [KO:K00799] [EC:2.5.1.18]
            26281  FGF20; fibroblast growth factor 20 [KO:K04358]
            27006  FGF22; fibroblast growth factor 22 [KO:K04358]
            27330  RPS6KA6; ribosomal protein S6 kinase A6 [KO:K04373] [EC:2.7.11.1]
            2770  GNAI1; G protein subunit alpha i1 [KO:K04630]
            2771  GNAI2; G protein subunit alpha i2 [KO:K04630]
            2773  GNAI3; G protein subunit alpha i3 [KO:K04630]
            2778  GNAS; GNAS complex locus [KO:K04632]
            28514  DLL1; delta like canonical Notch ligand 1 [KO:K06051]
            2885  GRB2; growth factor receptor bound protein 2 [KO:K04364]
            2938  GSTA1; glutathione S-transferase alpha 1 [KO:K00799] [EC:2.5.1.18]
            2939  GSTA2; glutathione S-transferase alpha 2 [KO:K00799] [EC:2.5.1.18]
            2940  GSTA3; glutathione S-transferase alpha 3 [KO:K00799] [EC:2.5.1.18]
            2941  GSTA4; glutathione S-transferase alpha 4 [KO:K00799] [EC:2.5.1.18]
            2944  GSTM1; glutathione S-transferase mu 1 [KO:K00799] [EC:2.5.1.18]
            2946  GSTM2; glutathione S-transferase mu 2 [KO:K00799] [EC:2.5.1.18]
            2947  GSTM3; glutathione S-transferase mu 3 [KO:K00799] [EC:2.5.1.18]
            2948  GSTM4; glutathione S-transferase mu 4 [KO:K00799] [EC:2.5.1.18]
            2949  GSTM5; glutathione S-transferase mu 5 [KO:K00799] [EC:2.5.1.18]
            2952  GSTT1; glutathione S-transferase theta 1 [KO:K00799] [EC:2.5.1.18]
            2953  GSTT2; glutathione S-transferase theta 2 (gene/pseudogene) [KO:K00799] [EC:2.5.1.18]
            3265  HRAS; HRas proto-oncogene, GTPase [KO:K02833]
            331  XIAP; X-linked inhibitor of apoptosis [KO:K04725] [EC:2.3.2.27]
            332  BIRC5; baculoviral IAP repeat containing 5 [KO:K08731]
            3320  HSP90AA1; heat shock protein 90 alpha family class A member 1 [KO:K04079]
            3326  HSP90AB1; heat shock protein 90 alpha family class B member 1 [KO:K04079]
            367  AR; androgen receptor [KO:K08557]
            3717  JAK2; Janus kinase 2 [KO:K04447] [EC:2.7.10.2]
            3725  JUN; Jun proto-oncogene, AP-1 transcription factor subunit [KO:K04448]
            3836  KPNA1; karyopherin subunit alpha 1 [KO:K23940]
            3837  KPNB1; karyopherin subunit beta 1 [KO:K14293]
            3838  KPNA2; karyopherin subunit alpha 2 [KO:K15043]
            3839  KPNA3; karyopherin subunit alpha 3 [KO:K23583]
            3840  KPNA4; karyopherin subunit alpha 4 [KO:K23583]
            3841  KPNA5; karyopherin subunit alpha 5 [KO:K15042]
            3845  KRAS; KRAS proto-oncogene, GTPase [KO:K07827]
            402569  KPNA7; karyopherin subunit alpha 7 [KO:K15043]
            405  ARNT; aryl hydrocarbon receptor nuclear translocator [KO:K09097]
            406881  MIRLET7A1; microRNA let-7a-1 [KO:K16980]
            406882  MIRLET7A2; microRNA let-7a-2 [KO:K16980]
            406883  MIRLET7A3; microRNA let-7a-3 [KO:K16980]
            406884  MIRLET7B; microRNA let-7b [KO:K16980]
            406885  MIRLET7C; microRNA let-7c [KO:K16980]
            406886  MIRLET7D; microRNA let-7d [KO:K16980]
            406887  MIRLET7E; microRNA let-7e [KO:K16980]
            406888  MIRLET7F1; microRNA let-7f-1 [KO:K16980]
            406889  MIRLET7F2; microRNA let-7f-2 [KO:K16980]
            406890  MIRLET7G; microRNA let-7g [KO:K16980]
            406891  MIRLET7I; microRNA let-7i [KO:K16980]
            406933  MIR141; microRNA 141 [KO:K17018]
            407021  MIR29A; microRNA 29a [KO:K16995]
            407024  MIR29B1; microRNA 29b-1 [KO:K16995]
            407025  MIR29B2; microRNA 29b-2 [KO:K16995]
            407026  MIR29C; microRNA 29c [KO:K16995]
            407054  MIR98; microRNA 98 [KO:K16980]
            408  ARRB1; arrestin beta 1 [KO:K04439]
            409  ARRB2; arrestin beta 2 [KO:K04439]
            4257  MGST1; microsomal glutathione S-transferase 1 [KO:K00799] [EC:2.5.1.18]
            4258  MGST2; microsomal glutathione S-transferase 2 [KO:K00799] [EC:2.5.1.18]
            4259  MGST3; microsomal glutathione S-transferase 3 [KO:K00799] [EC:2.5.1.18]
            4609  MYC; MYC proto-oncogene, bHLH transcription factor [KO:K04377]
            468  ATF4; activating transcription factor 4 [KO:K04374]
            4790  NFKB1; nuclear factor kappa B subunit 1 [KO:K02580]
            4853  NOTCH2; notch receptor 2 [KO:K20994]
            4893  NRAS; NRAS proto-oncogene, GTPase [KO:K07828]
            5241  PGR; progesterone receptor [KO:K08556]
            5290  PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [KO:K00922] [EC:2.7.1.153]
            5291  PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta [KO:K00922] [EC:2.7.1.153]
            5293  PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [KO:K00922] [EC:2.7.1.153]
            5295  PIK3R1; phosphoinositide-3-kinase regulatory subunit 1 [KO:K02649]
            5296  PIK3R2; phosphoinositide-3-kinase regulatory subunit 2 [KO:K02649]
            54490  UGT2B28; UDP glucuronosyltransferase family 2 member B28 [KO:K00699] [EC:2.4.1.17]
            54567  DLL4; delta like canonical Notch ligand 4 [KO:K06051]
            54575  UGT1A10; UDP glucuronosyltransferase family 1 member A10 [KO:K00699] [EC:2.4.1.17]
            54576  UGT1A8; UDP glucuronosyltransferase family 1 member A8 [KO:K00699] [EC:2.4.1.17]
            54577  UGT1A7; UDP glucuronosyltransferase family 1 member A7 [KO:K00699] [EC:2.4.1.17]
            54578  UGT1A6; UDP glucuronosyltransferase family 1 member A6 [KO:K00699] [EC:2.4.1.17]
            54579  UGT1A5; UDP glucuronosyltransferase family 1 member A5 [KO:K00699] [EC:2.4.1.17]
            54600  UGT1A9; UDP glucuronosyltransferase family 1 member A9 [KO:K00699] [EC:2.4.1.17]
            5465  PPARA; peroxisome proliferator activated receptor alpha [KO:K07294]
            54657  UGT1A4; UDP glucuronosyltransferase family 1 member A4 [KO:K00699] [EC:2.4.1.17]
            54658  UGT1A1; UDP glucuronosyltransferase family 1 member A1 [KO:K00699] [EC:2.4.1.17]
            54659  UGT1A3; UDP glucuronosyltransferase family 1 member A3 [KO:K00699] [EC:2.4.1.17]
            54852  PAQR5; progestin and adipoQ receptor family member 5 [KO:K25041]
            55584  CHRNA9; cholinergic receptor nicotinic alpha 9 subunit [KO:K04810]
            5566  PRKACA; protein kinase cAMP-activated catalytic subunit alpha [KO:K04345] [EC:2.7.11.11]
            5567  PRKACB; protein kinase cAMP-activated catalytic subunit beta [KO:K04345] [EC:2.7.11.11]
            5568  PRKACG; protein kinase cAMP-activated catalytic subunit gamma [KO:K04345] [EC:2.7.11.11]
            5578  PRKCA; protein kinase C alpha [KO:K02677] [EC:2.7.11.13]
            5579  PRKCB; protein kinase C beta [KO:K19662] [EC:2.7.11.13]
            5582  PRKCG; protein kinase C gamma [KO:K19663] [EC:2.7.11.13]
            5594  MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
            5595  MAPK3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
            5604  MAP2K1; mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2]
            5605  MAP2K2; mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2]
            572  BAD; BCL2 associated agonist of cell death [KO:K02158]
            574537  UGT2A2; UDP glucuronosyltransferase family 2 member A2 [KO:K00699] [EC:2.4.1.17]
            5894  RAF1; Raf-1 proto-oncogene, serine/threonine kinase [KO:K04366] [EC:2.7.11.1]
            5925  RB1; RB transcriptional corepressor 1 [KO:K06618]
            595  CCND1; cyclin D1 [KO:K04503]
            596  BCL2; BCL2 apoptosis regulator [KO:K02161]
            5970  RELA; RELA proto-oncogene, NF-kB subunit [KO:K04735]
            604  BCL6; BCL6 transcription repressor [KO:K15618]
            6195  RPS6KA1; ribosomal protein S6 kinase A1 [KO:K04373] [EC:2.7.11.1]
            6196  RPS6KA2; ribosomal protein S6 kinase A2 [KO:K04373] [EC:2.7.11.1]
            6197  RPS6KA3; ribosomal protein S6 kinase A3 [KO:K04373] [EC:2.7.11.1]
            6198  RPS6KB1; ribosomal protein S6 kinase B1 [KO:K04688] [EC:2.7.11.1]
            6199  RPS6KB2; ribosomal protein S6 kinase B2 [KO:K04688] [EC:2.7.11.1]
            6256  RXRA; retinoid X receptor alpha [KO:K08524]
            6257  RXRB; retinoid X receptor beta [KO:K08525]
            6258  RXRG; retinoid X receptor gamma [KO:K08526]
            64764  CREB3L2; cAMP responsive element binding protein 3 like 2 [KO:K09048]
            653689  GSTT2B; glutathione S-transferase theta 2B [KO:K00799] [EC:2.5.1.18]
            6654  SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 [KO:K03099]
            6655  SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 [KO:K03099]
            6714  SRC; SRC proto-oncogene, non-receptor tyrosine kinase [KO:K05704] [EC:2.7.10.2]
            6774  STAT3; signal transducer and activator of transcription 3 [KO:K04692]
            6776  STAT5A; signal transducer and activator of transcription 5A [KO:K11223]
            6777  STAT5B; signal transducer and activator of transcription 5B [KO:K11224]
            688  KLF5; KLF transcription factor 5 [KO:K09206]
            7184  HSP90B1; heat shock protein 90 beta family member 1 [KO:K09487]
            7363  UGT2B4; UDP glucuronosyltransferase family 2 member B4 [KO:K00699] [EC:2.4.1.17]
            7364  UGT2B7; UDP glucuronosyltransferase family 2 member B7 [KO:K00699] [EC:2.4.1.17]
            7365  UGT2B10; UDP glucuronosyltransferase family 2 member B10 [KO:K00699] [EC:2.4.1.17]
            7366  UGT2B15; UDP glucuronosyltransferase family 2 member B15 [KO:K00699] [EC:2.4.1.17]
            7367  UGT2B17; UDP glucuronosyltransferase family 2 member B17 [KO:K00699] [EC:2.4.1.17]
            7421  VDR; vitamin D receptor [KO:K08539]
            7422  VEGFA; vascular endothelial growth factor A [KO:K05448]
            7471  WNT1; Wnt family member 1 [KO:K03209]
            773  CACNA1A; calcium voltage-gated channel subunit alpha1 A [KO:K04344]
            774  CACNA1B; calcium voltage-gated channel subunit alpha1 B [KO:K04849]
            775  CACNA1C; calcium voltage-gated channel subunit alpha1 C [KO:K04850]
            776  CACNA1D; calcium voltage-gated channel subunit alpha1 D [KO:K04851]
            778  CACNA1F; calcium voltage-gated channel subunit alpha1 F [KO:K04853]
            779  CACNA1S; calcium voltage-gated channel subunit alpha1 S [KO:K04857]
            79799  UGT2A3; UDP glucuronosyltransferase family 2 member A3 [KO:K00699] [EC:2.4.1.17]
            79852  EPHX3; epoxide hydrolase 3 [KO:K22368] [EC:3.3.2.10]
            84699  CREB3L3; cAMP responsive element binding protein 3 like 3 [KO:K09048]
            8503  PIK3R3; phosphoinositide-3-kinase regulatory subunit 3 [KO:K02649]
            85315  PAQR8; progestin and adipoQ receptor family member 8 [KO:K25040]
            8600  TNFSF11; TNF superfamily member 11 [KO:K05473]
            8817  FGF18; fibroblast growth factor 18 [KO:K04358]
            8822  FGF17; fibroblast growth factor 17 [KO:K04358]
            8823  FGF16; fibroblast growth factor 16 [KO:K04358]
            896  CCND3; cyclin D3 [KO:K10152]
            89832  CHRFAM7A; CHRNA7 (exons 5-10) and FAM7A (exons A-E) fusion [KO:K04809]
            9049  AIP; AHR interacting HSP90 co-chaperone [KO:K17767]
            90993  CREB3L1; cAMP responsive element binding protein 3 like 1 [KO:K09048]
            9314  KLF4; KLF transcription factor 4 [KO:K17846]
            9446  GSTO1; glutathione S-transferase omega 1 [KO:K00799] [EC:2.5.1.18]
            9586  CREB5; cAMP responsive element binding protein 5 [KO:K09047]
            9641  IKBKE; inhibitor of nuclear factor kappa B kinase subunit epsilon [KO:K07211] [EC:2.7.11.10]
            990  CDC6; cell division cycle 6 [KO:K02213]
            993  CDC25A; cell division cycle 25A [KO:K06645] [EC:3.1.3.48]
            9970  NR1I3; nuclear receptor subfamily 1 group I member 3 [KO:K08541]
COMPOUND    C00076  Calcium cation
            C00410  Progesterone
            C00547  L-Noradrenaline
            C00575  3',5'-Cyclic AMP
            C00745  Nicotine
            C00780  Serotonin
            C00788  L-Adrenaline
            C00951  Estradiol-17beta
            C03690  Bis(2-ethylhexyl)phthalate
            C04623  DDT
            C05981  Phosphatidylinositol-3,4,5-trisphosphate
            C06697  Arsenite
            C06790  Trichloroethene
            C06916  Clofibrate
            C07020  Gemfibrozil
            C07434  Phenobarbital
            C07535  Benzo[a]pyrene
            C07557  2,3,7,8-Tetrachlorodibenzodioxin
            C08150  Medroxyprogesterone acetate
            C11042  Hexachlorobenzene
            C11150  Trichloroacetate
            C11371  Nafenopin
            C11906  Sodium arsenite
            C13624  Bisphenol A
            C14240  Di(2-ethylhexyl) adipate
            C14573  3,3',4,4',5-Pentachlorobiphenyl
            C15995  Bombesin
            C16452  N'-Nitrosonornicotine
            C16453  4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone
REFERENCE   PMID:15660110
  AUTHORS   Luch A.
  TITLE     Nature and nurture - lessons from chemical carcinogenesis.
  JOURNAL   Nat Rev Cancer 5:113-25 (2005)
            DOI:10.1038/nrc1546
REFERENCE   PMID:19631282
  AUTHORS   Hernandez LG, van Steeg H, Luijten M, van Benthem J
  TITLE     Mechanisms of non-genotoxic carcinogens and importance of a weight of evidence approach.
  JOURNAL   Mutat Res 682:94-109 (2009)
            DOI:10.1016/j.mrrev.2009.07.002
REFERENCE   PMID:21444681
  AUTHORS   Wu CH, Lee CH, Ho YS
  TITLE     Nicotinic acetylcholine receptor-based blockade: applications of molecular targets for cancer therapy.
  JOURNAL   Clin Cancer Res 17:3533-41 (2011)
            DOI:10.1158/1078-0432.CCR-10-2434
REFERENCE   PMID:19194381
  AUTHORS   Schuller HM
  TITLE     Is cancer triggered by altered signalling of nicotinic acetylcholine receptors?
  JOURNAL   Nat Rev Cancer 9:195-205 (2009)
            DOI:10.1038/nrc2590
REFERENCE   PMID:21541211
  AUTHORS   Singh S, Pillai S, Chellappan S
  TITLE     Nicotinic acetylcholine receptor signaling in tumor growth and metastasis.
  JOURNAL   J Oncol 2011:456743 (2011)
            DOI:10.1155/2011/456743
REFERENCE   PMID:31956359
  AUTHORS   Cheng WL, Chen KY, Lee KY, Feng PH, Wu SM
  TITLE     Nicotinic-nAChR signaling mediates drug resistance in lung cancer.
  JOURNAL   J Cancer 11:1125-1140 (2020)
            DOI:10.7150/jca.36359
REFERENCE   PMID:24827506
  AUTHORS   Grando SA
  TITLE     Connections of nicotine to cancer.
  JOURNAL   Nat Rev Cancer 14:419-29 (2014)
            DOI:10.1038/nrc3725
REFERENCE   PMID:24398389
  AUTHORS   Schaal C, Chellappan SP
  TITLE     Nicotine-mediated cell proliferation and tumor progression in smoking-related cancers.
  JOURNAL   Mol Cancer Res 12:14-23 (2014)
            DOI:10.1158/1541-7786.MCR-13-0541
REFERENCE   PMID:21640716
  AUTHORS   Improgo MR, Tapper AR, Gardner PD
  TITLE     Nicotinic acetylcholine receptor-mediated mechanisms in lung cancer.
  JOURNAL   Biochem Pharmacol 82:1015-21 (2011)
            DOI:10.1016/j.bcp.2011.05.020
REFERENCE   PMID:18262664
  AUTHORS   Egleton RD, Brown KC, Dasgupta P
  TITLE     Nicotinic acetylcholine receptors in cancer: multiple roles in proliferation and inhibition of apoptosis.
  JOURNAL   Trends Pharmacol Sci 29:151-8 (2008)
            DOI:10.1016/j.tips.2007.12.006
REFERENCE   PMID:24830349
  AUTHORS   Xue J, Yang S, Seng S
  TITLE     Mechanisms of Cancer Induction by Tobacco-Specific NNK and NNN.
  JOURNAL   Cancers (Basel) 6:1138-56 (2014)
            DOI:10.3390/cancers6021138
REFERENCE   PMID:21801603
  AUTHORS   Wen J, Fu JH, Zhang W, Guo M
  TITLE     Lung carcinoma signaling pathways activated by smoking.
  JOURNAL   Chin J Cancer 30:551-8 (2011)
            DOI:10.5732/cjc.011.10059
REFERENCE   PMID:28664511
  AUTHORS   Gankhuyag N, Lee KH, Cho JY
  TITLE     The Role of Nitrosamine (NNK) in Breast Cancer Carcinogenesis.
  JOURNAL   J Mammary Gland Biol Neoplasia 22:159-170 (2017)
            DOI:10.1007/s10911-017-9381-z
REFERENCE   PMID:22330135
  AUTHORS   Guo J, Kim D, Gao J, Kurtyka C, Chen H, Yu C, Wu D, Mittal A, Beg AA, Chellappan SP, Haura EB, Cheng JQ
  TITLE     IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer.
  JOURNAL   Oncogene 32:151-9 (2013)
            DOI:10.1038/onc.2012.39
REFERENCE   PMID:20106947
  AUTHORS   Chen RJ, Ho YS, Guo HR, Wang YJ
  TITLE     Long-term nicotine exposure-induced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and beta-adrenoceptors in human bladder cancer cells.
  JOURNAL   Toxicol Sci 115:118-30 (2010)
            DOI:10.1093/toxsci/kfq028
REFERENCE   PMID:20953833
  AUTHORS   Lee CH, Chang YC, Chen CS, Tu SH, Wang YJ, Chen LC, Chang YJ, Wei PL, Chang HW, Chang CH, Huang CS, Wu CH, Ho YS
  TITLE     Crosstalk between nicotine and estrogen-induced estrogen receptor activation induces alpha9-nicotinic acetylcholine receptor expression in human breast cancer cells.
  JOURNAL   Breast Cancer Res Treat 129:331-45 (2011)
            DOI:10.1007/s10549-010-1209-0
REFERENCE   PMID:16421368
  AUTHORS   Yager JD, Davidson NE
  TITLE     Estrogen carcinogenesis in breast cancer.
  JOURNAL   N Engl J Med 354:270-82 (2006)
            DOI:10.1056/NEJMra050776
REFERENCE   PMID:29229539
  AUTHORS   Murata M, Kang JH
  TITLE     Bisphenol A (BPA) and cell signaling pathways.
  JOURNAL   Biotechnol Adv 36:311-327 (2018)
            DOI:10.1016/j.biotechadv.2017.12.002
REFERENCE   PMID:28251049
  AUTHORS   Wang Z, Liu H, Liu S
  TITLE     Low-Dose Bisphenol A Exposure: A Seemingly Instigating Carcinogenic Effect on Breast Cancer.
  JOURNAL   Adv Sci (Weinh) 4:1600248 (2017)
            DOI:10.1002/advs.201600248
REFERENCE   PMID:28426875
  AUTHORS   Sauer SJ, Tarpley M, Shah I, Save AV, Lyerly HK, Patierno SR, Williams KP, Devi GR
  TITLE     Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells.
  JOURNAL   Carcinogenesis 38:252-260 (2017)
            DOI:10.1093/carcin/bgx003
REFERENCE   PMID:29769245
  AUTHORS   Chen QY, Costa M
  TITLE     PI3K/Akt/mTOR Signaling Pathway and the Biphasic Effect of Arsenic in Carcinogenesis.
  JOURNAL   Mol Pharmacol 94:784-792 (2018)
            DOI:10.1124/mol.118.112268
REFERENCE   PMID:32867363
  AUTHORS   Pedroza DA, Subramani R, Lakshmanaswamy R
  TITLE     Classical and Non-Classical Progesterone Signaling in Breast Cancers.
  JOURNAL   Cancers (Basel) 12:E2440 (2020)
            DOI:10.3390/cancers12092440
REFERENCE   PMID:26265122
  AUTHORS   Finlay-Schultz J, Sartorius CA
  TITLE     Steroid hormones, steroid receptors, and breast cancer stem cells.
  JOURNAL   J Mammary Gland Biol Neoplasia 20:39-50 (2015)
            DOI:10.1007/s10911-015-9340-5
REFERENCE   PMID:27368976
  AUTHORS   Valadez-Cosmes P, Vazquez-Martinez ER, Cerbon M, Camacho-Arroyo I
  TITLE     Membrane progesterone receptors in reproduction and cancer.
  JOURNAL   Mol Cell Endocrinol 434:166-75 (2016)
            DOI:10.1016/j.mce.2016.06.027
REFERENCE   PMID:33014829
  AUTHORS   Chen B, Ye P, Chen Y, Liu T, Cha JH, Yan X, Yang WH
  TITLE     Involvement of the Estrogen and Progesterone Axis in Cancer Stemness: Elucidating Molecular Mechanisms and Clinical Significance.
  JOURNAL   Front Oncol 10:1657 (2020)
            DOI:10.3389/fonc.2020.01657
REFERENCE   PMID:25568920
  AUTHORS   Murray IA, Patterson AD, Perdew GH
  TITLE     Aryl hydrocarbon receptor ligands in cancer: friend and foe.
  JOURNAL   Nat Rev Cancer 14:801-14 (2014)
            DOI:10.1038/nrc3846
REFERENCE   PMID:30003042
  AUTHORS   Larigot L, Juricek L, Dairou J, Coumoul X
  TITLE     AhR signaling pathways and regulatory functions.
  JOURNAL   Biochim Open 7:1-9 (2018)
            DOI:10.1016/j.biopen.2018.05.001
REFERENCE   PMID:27980293
  AUTHORS   Kawajiri K, Fujii-Kuriyama Y
  TITLE     The aryl hydrocarbon receptor: a multifunctional chemical sensor for host defense and homeostatic maintenance.
  JOURNAL   Exp Anim 66:75-89 (2017)
            DOI:10.1538/expanim.16-0092
REFERENCE   PMID:31552251
  AUTHORS   Hidaka T, Fujimura T, Aiba S
  TITLE     Aryl Hydrocarbon Receptor Modulates Carcinogenesis and Maintenance of Skin Cancers.
  JOURNAL   Front Med (Lausanne) 6:194 (2019)
            DOI:10.3389/fmed.2019.00194
REFERENCE   PMID:15900503
  AUTHORS   Mandal PK
  TITLE     Dioxin: a review of its environmental effects and its aryl hydrocarbon receptor biology.
  JOURNAL   J Comp Physiol B 175:221-30 (2005)
            DOI:10.1007/s00360-005-0483-3
REFERENCE   PMID:30951959
  AUTHORS   Miret NV, Pontillo CA, Zarate LV, Kleiman de Pisarev D, Cocca C, Randi AS
  TITLE     Impact of endocrine disruptor hexachlorobenzene on the mammary gland and breast cancer: The story thus far.
  JOURNAL   Environ Res 173:330-341 (2019)
            DOI:10.1016/j.envres.2019.03.054
REFERENCE   PMID:32526215
  AUTHORS   Zarate LV, Pontillo CA, Espanol A, Miret NV, Chiappini F, Cocca C, Alvarez L, de Pisarev DK, Sales ME, Randi AS
  TITLE     Angiogenesis signaling in breast cancer models is induced by hexachlorobenzene and chlorpyrifos, pesticide ligands of the aryl hydrocarbon receptor.
  JOURNAL   Toxicol Appl Pharmacol 401:115093 (2020)
            DOI:10.1016/j.taap.2020.115093
REFERENCE   PMID:25257533
  AUTHORS   L'Heritier F, Marques M, Fauteux M, Gaudreau L
  TITLE     Defining molecular sensors to assess long-term effects of pesticides on carcinogenesis.
  JOURNAL   Int J Mol Sci 15:17148-61 (2014)
            DOI:10.3390/ijms150917148
REFERENCE   PMID:17189671
  AUTHORS   Kitamura M, Kasai A
  TITLE     Cigarette smoke as a trigger for the dioxin receptor-mediated signaling pathway.
  JOURNAL   Cancer Lett 252:184-94 (2007)
            DOI:10.1016/j.canlet.2006.11.015
REFERENCE   PMID:26600562
  AUTHORS   Smith MT, Guyton KZ, Gibbons CF, Fritz JM, Portier CJ, Rusyn I, DeMarini DM, Caldwell JC, Kavlock RJ, Lambert PF, Hecht SS, Bucher JR, Stewart BW, Baan RA, Cogliano VJ, Straif K
  TITLE     Key Characteristics of Carcinogens as a Basis for Organizing Data on Mechanisms of Carcinogenesis.
  JOURNAL   Environ Health Perspect 124:713-21 (2016)
            DOI:10.1289/ehp.1509912
REFERENCE   PMID:31366862
  AUTHORS   Yoshinari K
  TITLE     Role of Nuclear Receptors PXR and CAR in Xenobiotic-Induced Hepatocyte Proliferation and Chemical Carcinogenesis.
  JOURNAL   Biol Pharm Bull 42:1243-1252 (2019)
            DOI:10.1248/bpb.b19-00267
REFERENCE   PMID:26136231
  AUTHORS   Yoo HS, Cichocki JA, Kim S, Venkatratnam A, Iwata Y, Kosyk O, Bodnar W, Sweet S, Knap A, Wade T, Campbell J, Clewell HJ, Melnyk SB, Chiu WA, Rusyn I
  TITLE     The Contribution of Peroxisome Proliferator-Activated Receptor Alpha to the Relationship Between Toxicokinetics and Toxicodynamics of Trichloroethylene.
  JOURNAL   Toxicol Sci 147:339-49 (2015)
            DOI:10.1093/toxsci/kfv134
REFERENCE   PMID:20414453
  AUTHORS   Pyper SR, Viswakarma N, Yu S, Reddy JK
  TITLE     PPARalpha: energy combustion, hypolipidemia, inflammation and cancer.
  JOURNAL   Nucl Recept Signal 8:e002 (2010)
            DOI:10.1621/nrs.08002
REFERENCE   PMID:20049115
  AUTHORS   Guyton KZ, Chiu WA, Bateson TF, Jinot J, Scott CS, Brown RC, Caldwell JC
  TITLE     A reexamination of the PPAR-alpha activation mode of action as a basis for assessing human cancer risks of environmental contaminants.
  JOURNAL   Environ Health Perspect 117:1664-72 (2009)
            DOI:10.1289/ehp.0900758
REL_PATHWAY hsa00980  Metabolism of xenobiotics by cytochrome P450
            hsa03320  PPAR signaling pathway
            hsa04010  MAPK signaling pathway
            hsa04024  cAMP signaling pathway
            hsa04150  mTOR signaling pathway
            hsa04151  PI3K-Akt signaling pathway
            hsa04370  VEGF signaling pathway
            hsa04915  Estrogen signaling pathway
            hsa05204  Chemical carcinogenesis - DNA adducts
            hsa05206  MicroRNAs in cancer
            hsa05208  Chemical carcinogenesis - reactive oxygen species
KO_PATHWAY  ko05207
///
